Trius IPO Idling

Xconomy San Diego — 

San Diego’s Trius Therapeutics has again delayed its long-planned $78 million initial public offering, which was scheduled to go out this week, according a report today by Bloomberg News. Renaissance Capital, which listed Trius among the expected IPOs this week, continues to list the Trius offering as “day to day.” Trius, founded in 2004, has been developing technology for a new class of antibiotics. The company’s lead drug is an antibiotic for treating MRSA, Methicillin-resistant Staphylococcus aureus.